Patents Examined by Jeffrey H Murray
-
Patent number: 11974982Abstract: Compositions comprising an active oxygen-responsive antioxidant crystal, methods of making them, and methods for controlling the dissolution rate and/or altering the crystallization behavior of an antioxidant are disclosed. The crystals comprise an antioxidant and a disulfide- or diselenide-crosslinked polymer that is adsorbed onto a surface of the antioxidant. Upon exposure to an active-oxygen stimulus, the polymer de-crosslinks to release the antioxidant from the composition in an amount effective to counteract the stimulus. While prior approaches to altering dissolution rates have relied on passive zero- or first-order kinetics that are independent of ROS levels, the inventive compositions actively respond by releasing antioxidant in an amount proportional to the concentration of active-oxygen species present. The crystallization methods are simple and scalable.Type: GrantFiled: March 30, 2021Date of Patent: May 7, 2024Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Hyunjoon Kong, Byoungsoo Kim, Jonghwi Lee, Youngjun Kim, Ryan Cree Miller
-
Patent number: 11975003Abstract: Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of viral RNA polymerase. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or suppression of a Zika virus infection or a disease or condition associated with a Zika virus infection.Type: GrantFiled: March 1, 2021Date of Patent: May 7, 2024Assignee: BIOCRYST PHARMACEUTICALS, INC.Inventors: Yarlagadda S. Babu, Pravin L Kotian, Shanta Bantia
-
Patent number: 11970502Abstract: The present invention discloses macrocyclic compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 3, 2022Date of Patent: April 30, 2024Assignee: Enanta Pharmaceuticals, Inc.Inventors: Jiajun Zhang, Xiaowen Peng, Yat Sun Or
-
Patent number: 11964975Abstract: Novel 5-substituted aminopyrimido[6?,1?:2,3]imidazo[4,5-c][2,6]naphthyridine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The 5-substituted aminopyrimido[6?,1?:2,3]imidazo[4,5-c][2,6]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.Type: GrantFiled: August 21, 2023Date of Patent: April 23, 2024Assignee: KING FAISAL UNIVERSITYInventors: Michelyne Haroun, Christophe Tratrat
-
Patent number: 11964986Abstract: The present invention relates to 9-oxo-9,10-dihydro-6H-pyrano[3,2-b:4,5-b?]dipyridine-8-carboxylic acid derivatives, their manufacture, pharmaceutical compositions containing them and their use as a medicament.Type: GrantFiled: July 3, 2023Date of Patent: April 23, 2024Assignee: REJUVERON TELOMERE THERAPEUTICS AGInventors: Patrick Schnider, Fedor Romanov Michailidis, Chien-Chi Hsiao
-
Patent number: 11958861Abstract: The present application provides spirocyclic lactam compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.Type: GrantFiled: February 24, 2022Date of Patent: April 16, 2024Assignee: Incyte CorporationInventors: Stacey Shepard, Charles Cole, Nikoo Falahatpisheh, Kai Liu, Lixin Shao, Darius Vrubliauskas, Liangxing Wu, Wenqing Yao, Eddy W. Yue
-
Patent number: 11958863Abstract: The present disclosure includes compounds, kits, and assay procedures for use in determining the levels of certain types of drugs in samples that contain specific binding proteins for the drugs. The present disclosure includes analog compounds useful for displacing the drugs from their endogenous binding proteins, and kits including same, as well as methods that utilize these displacers as binding competitors in pharmaceutical assays.Type: GrantFiled: October 25, 2019Date of Patent: April 16, 2024Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Tie Wei, Zhu Teng, Martin Drinan, Jie Li
-
Patent number: 11958853Abstract: Novel 6-substituted aminopyrazino[2?,1?:2,3]imidazo[4,5-c][1,7]naphthyridine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The 6-substituted aminopyrazino[2?,1?:2,3]imidazo[4,5-c][1,7]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.Type: GrantFiled: August 18, 2023Date of Patent: April 16, 2024Assignee: KING FAISAL UNIVERSITYInventors: Michelyne Haroun, Christophe Tratrat
-
Patent number: 11958864Abstract: The present invention relates to Tetracyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein R1 is as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Heterocycle Compound, and methods of using the Tetracyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.Type: GrantFiled: February 14, 2022Date of Patent: April 16, 2024Assignee: Merck Sharp & Dohme LLCInventors: Timothy John Hartingh, John A. McCauley, Tao Yu, Yonglian Zhang
-
Patent number: 11952368Abstract: Provided are a fibroblast activation protein inhibitor (FAPI) dimer compound, an FAPI dimer-based positron emission tomography (PET) imaging agent for tumor diagnosis, and a preparation method and use thereof. An amphiphilic polyethylene glycol (PEG) chain and a dimerized structure of FAPI in the FAPI dimer compound with a structure shown in formula I can improve the in vivo kinetic properties of the compound and prolong a residence time of the compound in a tumor, thereby improving the uptake and imaging effects in the tumor. The accurate tumor diagnosis can be achieved by labeling the FAPI dimer compound with a diagnostic nuclide (68Ga), which has promising application prospects in PET imaging for diagnosis and in the preparation of a therapeutic nuclide (such as 177Lu or 90Y)-labeled drug for treating a FAP-?-expressing tumor.Type: GrantFiled: September 29, 2022Date of Patent: April 9, 2024Assignee: Xiamen UniversityInventors: Haojun Chen, Liang Zhao, Qin Lin, Kaili Fu, Yizhen Pang, Zhide Guo, Jianyang Fang, Long Sun, Hua Wu
-
Patent number: 11952349Abstract: The disclosure relates to anti-cancer compounds derived from a payload which binds to poly(ADP-ribose) polymerase (PARP) and a nuclear steroid-targeting epitope (B of Formula I), which components are covalently linked via a linker, to products containing the same, as well as to methods of their use and preparation.Type: GrantFiled: November 12, 2020Date of Patent: April 9, 2024Assignee: Nuvation Bio Inc.Inventors: Son Minh Pham, Jayakanth Kankanala, Jeremy Pettigrew, Christopher Paul Miller
-
Patent number: 11952346Abstract: Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein D, W, Z, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.Type: GrantFiled: December 8, 2021Date of Patent: April 9, 2024Assignee: Escient Pharmaceuticals, Inc.Inventors: Marion Lanier, Marcus Boehm, Liming Huang, Esther Martinborough, Marcos Sainz, Brandon Selfridge, Adam Yeager
-
Patent number: 11945785Abstract: Disclosed herein are heterocyclic compounds, for example, according to the following formula and analogs thereof: that inhibit the activity of FLT3. Also described are specific covalent inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.Type: GrantFiled: December 29, 2022Date of Patent: April 2, 2024Assignee: Biomea Fusion, Inc.Inventors: David Sperandio, Xiaodong Wang, Thorsten A. Kirschberg, James T. Palmer, Thomas Butler, Solomon B. Ungashe, Neil Howard Squires, Nan-Horng Lin, Ravindra B. Upasani, Amna Trinity-Turjuman Adam, Yongli Su, Thu Phan
-
Patent number: 11931412Abstract: The present invention provides methods for treating pruritus having a neurogenic component in a subject in need thereof comprising administering a therapeutically effective amount of a JAK1 inhibitor based on a benzimidazole core, a purine core, or a pyrrolo pyridine core.Type: GrantFiled: February 4, 2021Date of Patent: March 19, 2024Assignee: Washington UniversityInventor: Brian Kim
-
Patent number: 11927590Abstract: Methods and systems for screening therapeutic compositions for the treatment of age-related macular degeneration (AMD) or for the prevention of progression of AMD, wherein retinal pigment epithelium cells (RPE) are cultured and the level of hypoxia-induced exosome release from the RPE cells is subsequently measured. In the present invention, the level of hypoxia-induced exosome release can be correlated with AMD onset and severity.Type: GrantFiled: June 11, 2021Date of Patent: March 12, 2024Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONAInventors: Brian S. McKay, Anna G. Figueroa, Nicole R. Congrove
-
Patent number: 11905283Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, R1, R2 and R3 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.Type: GrantFiled: December 22, 2020Date of Patent: February 20, 2024Assignee: NOVARTIS AGInventors: Zhuoliang Chen, Jorge Garcia Fortanet, Rajesh Karki, Matthew J. Lamarche, Dyuti Majumdar, Lawrence Blas Perez, Martin Sendzik, Troy Douglas Smith, Fan Yang, Bing Yu
-
Patent number: 11905292Abstract: The present invention is related to processes for preparing ruxolitinib, or a salt thereof, and related synthetic intermediates related thereto.Type: GrantFiled: August 17, 2021Date of Patent: February 20, 2024Assignee: Incyte CorporationInventors: Jiacheng Zhou, Shili Chen, Pingli Liu, David J. Meloni, James M. Parks, Yongchun Pan, Naijing Su, Michael Xia, Weiguo Liu
-
Patent number: 11897877Abstract: The present invention relates to compounds of formula I wherein R1, R4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.Type: GrantFiled: May 13, 2021Date of Patent: February 13, 2024Assignee: Cancer Research Technology LimitedInventors: Swen Hoelder, Julian Blagg, Savade Solanki, Hannah Woodward, Sebastien Gaston Andre Naud, Vassilios Bavetsias, Peter Sheldrake, Paolo Innocenti, Kwai-Ming J. Cheung, Butrus Atrash
-
Patent number: 11896559Abstract: The present disclosure provides methods of treatment using ophthalmic compositions comprising semifluorinated alkanes for keratoconjunctivitis sicca and/or Meibomian gland dysfunction, which methods provide for the enrichment of an ophthalmic tissue in the semifluorinated alkane, and optionally methods of delayed release of the semifluorinated alkane from the enriched ophthalmic tissue to the surface of the cornea and/or conjunctiva, and/or to the Meibomian gland.Type: GrantFiled: October 3, 2018Date of Patent: February 13, 2024Assignee: NOVALIQ GMBHInventors: Bernhard Günther, Frank Löscher, Hartmut Voss, Sonja Krösser, Kirsten Eickhoff, Daniela Willen, Markus Beier, Thomas Schlüter
-
Patent number: 11896592Abstract: Provided are certain triazolopyridines and triazolopyrazines of Formula 1, wherein X, Y, R1, R2, R3, R4 and R5 have any of the meanings described herein; processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of cell proliferative disorders.Type: GrantFiled: February 3, 2021Date of Patent: February 13, 2024Assignee: Hutchison Medipharma LimitedInventors: Wei-Guo Su, Hong Jia, Guangxiu Dai